Administration of Intravenous Immunoglobulin without Central Venous Catheter

Vías de administración para inmunoglobulina

The American Academy of Allergy, Asthma, and Immunology recommends that intravenous immunoglobulin (IGIV) can be administered through peripheral venous access, and a central venous catheter is not necessary for its administration 1
Clinical practice guidelines specifically advise against the placement of permanent central venous catheters solely for the purpose of administering IGIV, with a strength of evidence based on expert opinion 1

The American Society for Parenteral and Enteral Nutrition recommends that central venous access is primarily recommended for solutions with high osmolarity (>850 mOsm/L), with a moderate level of evidence 2, 3
Immunoglobulin preparations typically do not have an osmolarity high enough to require central venous access, based on low to moderate evidence 2
Central venous catheters carry significant risks of mechanical and infectious complications that should be avoided when not strictly necessary, with a high level of evidence 4

Peripheral access avoids complications associated with central catheters, such as pneumothorax, bloodstream infections, thrombosis, and hemothorax, with a high level of evidence 4
It allows for safe and effective administration in most patients requiring immunoglobulin, based on moderate evidence 1

The American Academy of Allergy, Asthma, and Immunology suggests that subcutaneous immunoglobulin (IGSC) is an excellent alternative for patients with difficult venous access, with a moderate level of evidence 1

Patients receiving immunoglobulin therapy should have regular monitoring of IgG trough levels, blood cell counts, and serum chemistry, based on expert opinion and low to moderate evidence 1